| INTRODUCTION
Asthma, allergies and related disorders have doubled in prevalence during recent decades and are among the most common chronic diseases in industrialized countries, with asthma affecting 26 million US children and adults and allergies affecting~42.5% of the population. [1] [2] [3] [4] A large proportion of asthma cases are characterized by an increase in serum immunoglobulin E (IgE) levels, 5 and a dose-response relationship between IgE levels and disease severity has been demonstrated. 6 Total
IgE is an important therapeutic target, and existing biological therapies (including omalizumab and recently approved reslizumab and mepolizumab) target IL-4, IL-5, IL-13 and IgE-specific pathways. 7 However, therapeutic trials of these biological agents only demonstrate benefits among subjects with more severe asthma subtypes. 7 These findings provide further evidence that asthma comprises a diverse range of immunological and clinical phenotypes, which require an equally diverse variety of personalized therapies.
Given the high heritability of IgE (estimated to be up to 0.8 in cord blood), 8 a better understanding of the causal genetic factors underlying IgE levels among individuals with asthma may lead to novel IgE-focused treatments for a subset of cases. While many of the genetic and genomic studies of total IgE levels have been performed in genetically heterogeneous populations, [9] [10] [11] [12] we hypothesized that investigating a more homogeneous population, specifically a semipopulation isolate (Costa Rican children with asthma), will enable the improved identification of novel biological targets. A genetic study of this population previously identified an association between polymorphisms in IL13 and serum IgE, eosinophil count and asthma exacerbations. 13 The aim of this study was to use a network genomics approach to identify novel differentially expressed genes and gene networks associated with serum total IgE in two populations with asthma: the "Genetics of Asthma in Costa Rica Study" (GACRS) and "The Childhood Asthma Management Program" (CAMP) cohort. By comparing the semi-isolated GACRS population, which is characterized by a high asthma prevalence (24% in children), a more homogenous genetic background and a highly allergic population, to the heterogeneous CAMP population, we aimed to improve the robustness and generalizability of our findings. 14 These approaches using gene coexpression networks have been useful in identifying gene signatures associated with severe subtypes of asthma, but have not previously been employed in association with IgE levels in asthma. 15, 16 Elucidating the biology underlying serum total IgE, particularly as it pertains to asthma severity, is vital to develop improved strategies for the prevention, management and treatment of asthma and allergic conditions.
| ME TH ODS

| GACRS population and study design
Participants in the GACRS are members of a Hispanic population semi-isolated from the Central Valley of Costa Rica, which has one of the highest rates of asthma world-wide. 17 From February 2001 to 
| CAMP population and study design
CAMP is a multi-centre, randomized, double-masked, clinical trial designed to determine the long-term (~16.5 years of follow-up) effects of three inhaled treatments for mild-to-moderate asthma in children aged 5 to 12 at baseline: placebo, nedocromil or budesonide. 19 Asthma was defined based on having both a clinical history (with the presence of symptoms or the use of an inhaled bronchodilator at least twice weekly or the use of daily medication for asthma) and airway responsiveness to methacholine (as measured by 20% decline in forced expiratory volume (FEV1) at doses ≤12.5 mg/ mL of methacholine). A follow-up study to the primary trial extracted blood samples from 620 CAMP subjects at early adulthood (aged 16-25, a mean 11.6 years (range 10-13.5 years) after enrolment) for gene expression profiling using the same Illumina HumanHT chip and concurrently measured serum total IgE (two individuals for whom IgE was measured >18 months from gene expression profiling were removed from the analysis). Of these, 610 subjects had complete phenotype data for downstream analysis.
| Gene expression profiling
In both populations, whole-blood gene expression was assayed with 47 009 probes on the Illumina HumanHT-12 v4 Expression BeadChip (Illumina, Inc., San Diego, CA, USA) that passed stringent and commonly used quality control metrics. 20 Expression data were log 2 -transformed and quantile-normalized using the R package "lumi" (version 2.22) and Bioconductor. 21 Principal components of gene expression were generated both for GACRS and for CAMP. Prior to downstream statistical analyses, a standard non-specific variance filter was applied to the expression data using the R package This resulted in a total of 25 059 and 24 971 gene probes for the GACRS and CAMP analyses, respectively. All 24 971 genes in the CAMP data set were also represented in the larger GACRS data set.
| Statistical analyses
All analyses were first conducted in the GACRS and then conducted independently in the CAMP population for validation of the significant findings using a parallel analysis design and identical methods.
As in previous study designs, 9, 23 we aimed to compare findings that replicated in both a relative genetic isolate (GACRS) and an outbred population (CAMP). 
| Differential gene expression analysis
Generalized linear regression models (GLM) 24 were constructed to identify differentially expressed genes associated with log-transformed total serum IgE levels. We adjusted for age (due to the age differences in our two cohorts), sex (due to prior genetic associations with IgE 24 ) and the first two principal components of gene expression to account for any batch effects (all concurrent with serum total IgE measurements). The Benjamini-Hochberg procedure was used to control the false discovery rate (FDR) with q-value set at 0.05. 
| Gene network analysis
Gene expression modules have previously been shown to be enriched for biological functions. We hypothesized that using weighted gene coexpression network analysis (WGCNA), 26 we would be able to refine the results of the regression analysis to identify networks of highly significant genes that are expressed together in groups or "modules" of coexpressed genes. These modules can then be related to phenotypic and baseline traits. WGCNA was used to generate a network describing correlation patterns between the genes. Using hierarchical clustering based on topological overlap and applying a soft thresholding power of 5, chosen to achieve a scalefree topology fitting index >0.9 (explaining over 90% of the variance), the interconnectedness between all possible gene pairs was quantified and they were assigned to gene coexpression modules. A dynamic clustering approach was utilized with a deep split of 0.8, and a minimum module size of 30 was specified, to further refine the degree of detail each module contained without influencing module structure, based on recommended defaults. 26 We then removed all uncorrelated transcripts that were assigned to the grey module, a module typically reserved for transcripts that do not map to a discrete module. Each module was summarized by an eigenvalue based on its first principal component, and the association between the module eigenvalues and log 10 -transformed serum total IgE, after adjustment for age at gene expression profiling and gender, was computed using multivariable linear regression.
| Pathway enrichment analysis
Pathway enrichment analysis using Gene Ontology (GO) terms was performed using an online tool from the GO Consortium (http://geneontology.org/page/go-enrichment-analysis), relying on the PANTHER Overrepresentation Test (release 20171205) 27 with an α < 0.01, fold enrichment >5 and containing at least 2 genes transcripts from our study included in the GO category. We identified key biological pathways among (a) the differentially expressed genes identified using the multivariate linear regression models and (b) the gene transcripts of WGCNA-generated modules associated with serum IgE.
| Overrepresentation analysis
We conducted gene set overrepresentation analysis using replicated gene transcripts common to both the GACRS and CAMP population, 
| Study populations
The baseline characteristics of the GACRS and CAMP study populations are described in Table 1 . The GACRS comprises a Hispanic/ Latino population, while CAMP was predominantly white European (68%) and only 10% Hispanic/Latino. The proportion of males and females in the two cohorts were similar, with a higher percentage of males in both. The age of asthma onset was young in both cohorts:
2.4 years in the GACRS and 3.0 years in CAMP. Gene expression profiling and the measurement of serum IgE levels were performed on blood samples taken in childhood (mean: 9.1 years) in the GACRS and in early adulthood in CAMP (mean: 20.4 years). Importantly, there was no significant difference in serum IgE levels between the two cohorts, despite the age difference.
| Differential gene expression analysis
A total of 81 gene transcripts were significantly associated with serum IgE levels in the GACRS cohort after adjustment for age at expression profiling, gender and the first two principal components, and controlling for the FDR. Sixty-nine of these gene transcripts (85%) were positively associated with serum total IgE, and 12 (15%)
were negatively associated ( Figure 1 ). Differential gene expression analysis showed no association of these genes with atopic dermatitis or allergic rhinitis. Of these 81 gene transcripts, 42 (54%) were replicated in CAMP with a concordant direction of effect; all 42 were overexpressed with ncreasing IgE levels ( Figure 2 , Table S1 ). We then conducted a sensitivity analysis, adjusting for inhaled corticosteroid use in both populations, with 36 (86%) transcripts still significant (Table S1 ). Of note, all of the transcripts identified in CAMP remained significantly associated with IgE after adjusting for original treatment group from the CAMP randomized trial. The 42 transcripts replicated in CAMP and GACRS were nominally enriched (P < 0.01, fold enrichment>5, number of genes>1) for 32 biological processes (Table S2 ). Although none of these 32 processes was robust to the most stringent correction for multiple testing, Bonferroni correction, a number had biologically plausible functional annotations, particularly those related to immune responses, such as "regulation of T cell tolerance induction."
| Gene network analysis
The gene expression network analysis was first performed in the GACRS. The samples were clustered, resulting in the exclusion of three samples identified as outliers. From the 25 059 transcripts, hierarchical clustering based on the topological overlap then designated the 10 073 transcripts into 32 modules (43%) ( Figure S1A ).
Five modules, as summarized by their eigengenes, were associated with serum IgE level (α < 0.05) ( Figure S1A ). Only one module, containing 103 gene transcripts, was robust to correction for multiple testing (P = 4.8 × 10 -11 ). This module was also associated with the more stringent subtype of asthma (P = 0.002), defined by physician diagnosis and the presence of airway hyper-reactivity on methacholine challenge, but was not associated with allergic rhinitis or atopic dermatitis. The module was also not associated with inhaled corticosteroid use, but had a nominal association with oral steroid use in the last year (P = 0.04). Pathway enrichment analysis of these 103 transcripts identified 52 GO-defined biological processes (Table S3) , including 12 of the 32 processes identified in the differential gene expression analysis and additional processes relating to immune function.
WGCNA was then applied to the CAMP data set using the same network construction approach; one sample was excluded as an outlier. Within the remaining 611 samples, the gene transcripts were clustered into 40 modules including 15 120 transcripts (61%). Fourteen modules were associated with serum IgE levels after adjustment for age and gender (P < 0.05), and one module was robust to correction for multiple testing (P = 6.8 × 10 −14 ) ( Figure S1B ). This module was also associated with inhaled corticosteroid use (P = 0.0003).
This module contained 38 transcripts that were enriched for 25 biological processes (Table S4) . 
| 1657
To determine any genomic and biological similarities between the significant GACRS and CAMP modules, the overlap in terms of gene transcripts and enriched biological processes was computed. Of the 103 transcripts in the significant GACRS module and the 38 transcripts in the significant CAMP module, all 38 were common to both (Table S5) . Of the 52 and 25 enriched GO-defined biological processes from the GACRS and CAMP modules, respectively, 14
were common to both (Table S5) . Finally, the similarities between the differential gene expression analysis and the WGCNA analyses were compared (Figure 3 ). Thirty-one transcripts (Table 2) , and twelve enriched biological processes, including a number related to immune response, were common to both sets of analyses in both cohorts (Table 3 ) and further confirmed the similarities in results between the two independent populations. Based on the literature, eight of the thirty-one gene transcripts have been previously linked to IgE, while the remainder represent novel associations (Table 2 ).
| Overrepresentation analysis
To further clarify the immunological relevance of the 31 validated transcripts, we compared our gene set to a database of immunological signatures, yielding three gene sets that were enriched ( 
Comparison of the total IgE gene expression profiles generated using differential gene expression and network approaches all of transcripts reported in Table 2 remained significantly associated with IgE levels by differential gene expression even after adjusting for the use of inhaled corticosteroids.
Within the pathway enrichment analyses of the total IgE-associated transcripts, we identified the immune relevant GO category, "regulation of tolerance induction," which was highlighted due to T A B L E 2 Replicated gene transcripts (n = 31) associated with total IgE using two different statistical approaches in two distinct cohorts with asthma: GACRS and CAMP while activating regulatory T cells. 33 These findings are notable given that regulatory T cell activity is thought to be deficient in allergic asthma, 34 yet we found a positive association of increasing IgE with increased IDO1 and CLC. We hypothesize that this represents a regulatory mechanism induced to curb the allergic immune response in the setting of asthma. This hypothesis is supported by findings describing a spectrum of increased IDO1 activity that is higher among atopic individuals compared to healthy controls and highest among asymptomatic atopic subjects compared to symptomatic ones, suggesting that IDO1 may be involved in inducing a state of clinical unresponsiveness in allergic individuals. 35 Further study is needed to clarify the roles of IDO1 and serum IgE in asthma. to be less efficacious in humans than in mouse models. 40, 41 In addition, the leukotriene pathway has been a therapeutic target for asthma for decades, although specific inhibitors for LTC4S (leukotriene C4 synthase) have only recently been developed and evaluated in mouse models. 42, 43 The identification of these known targets using our analytical approach corroborates the possibility that the other transcripts in this set may be equally useful as therapeutic targets.
Other genes from our eosinophil-related gene sets have known associations with allergic asthma and may also have therapeutic or diagnostic potential, including CCL23, CLC, CEBPE, CAMK1, IDO1, SIGLEC8, SMPD3 and SPNS3. [44] [45] [46] [47] [48] [49] [50] [51] Potential therapeutic targets include cell surface receptors, such as Siglec8, an inhibitory receptor on eosinophils with polymorphisms associated with asthma. [45] [46] [47] CCL23 is an eosinophilic chemokine that has been identified as a possible biomarker for anti-IL13-targeted therapies. 48, 49 Several of these are enzymes expressed within eosinophils, such as CLC, IDO1, SMPD3 and SPNS3, and the latter two are both involved in the sphingolipid pathways, known to mediate airway hyperresponsiveness and mast cell activation. 50, 51 Another gene CAMK1 has been implicated as an asthma control gene, 20 but has not been identified previously with IgE or an allergy-related phenotype among individuals diagnosed with asthma. Of the calmodulin-dependent kinases, CAMK2 and CAMK4 have been implicated in bronchoconstriction and smooth muscle proliferation, 52, 53 suggesting that CAMK1 may also play a role in asthma pathogenesis.
We also report the expression of a number of novel genes, including EMR1, EMR4P and PIK3R6, which were significant in our data and have been shown to be up-regulated in eosinophilic asthma in other studies. These genes have no known mechanistic association with total IgE or asthma but have been implicated in allergic processes such as allergic rhinosinusitis and anaphylaxis. 54, 55 EMR1 and EMR4P encode G protein-coupled receptors that may be particularly useful as therapeutic targets. While these genes do not have known roles in IgE or asthma, their replication in both of our cohorts, as well as other published gene sets, implicates them as potentially novel biomarkers or therapeutic targets.
Our study design and analysis does have some limitations. The cross-sectional nature of the expression and phenotype data limit the ability to make true causal inferences. The use of whole-blood gene expression profiles may not be as physiologically relevant as lung tissue-specific profiling; however, the use of less invasive sampling methods allows for greater sample sizes and more robust replication. While it could prove useful to split the whole-blood expression data into specific cell populations, these techniques are in development and still face significant limitations, including concerns about accuracy and ability to detect expression profiles of cell subsets. 56, 57 Recent studies support the utility of whole-blood transcriptomics in the setting of asthma. 58, 59 We cannot exclude the possibility that these transcripts play a role in atopic disease in general; however, the WGCNA analysis showing an association with a stricter definition of asthma in the GACRS population, and a lack of association with either atopic dermatitis or allergic rhinitis, supports a more prominent role in allergic asthma. Also, GO-based enrichment analyses are subject to annotation bias and can often yield high-level information about biological processes that are ubiquitous to all cellular function; thus, we attempted to improve the biological rele- | 1661 studies of asthma, suggesting that they may represent novel therapeutic targets or biomarkers. Further functional validation of these transcripts and their roles in influencing total IgE and asthma will be essential to developing novel strategies for improved primary prevention, management and treatment of asthma.
